Literature DB >> 9294595

Consistent transient transfection of DNA into non-transformed human and murine T-lymphocytes.

R Q Cron1, L A Schubert, D B Lewis, C C Hughes.   

Abstract

The ability to analyze transcriptional regulation in non-transformed T-cells has been hampered by the inability to reproducibly transiently transfect these cells with DNA constructs. We have previously demonstrated that normal human whole mononuclear and CD4 T-cells can be consistently transiently transfected with plasmid DNA. Human cells were most receptive to plasmid DNA uptake between 19.5 and 20 h after prestimulation with a submitogenic dose of the polyclonal T-cell activator, PHA. Here we report an alteration and optimization of this protocol for non-transformed murine splenic T-cells, using concanavalin A instead of PHA as the preactivation stimulus. When coupled with the high sensitivity of luciferase reporter gene constructs, this protocol facilitates the analysis of a variety of T-cell-specific promoters in non-transformed T-cells. In addition, we directly demonstrate that murine T-cells are specifically transiently transfected among a population of whole mononuclear cells by using an expression vector for green fluorescent protein.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294595     DOI: 10.1016/s0022-1759(97)00065-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Early growth response-1 is required for CD154 transcription.

Authors:  Randy Q Cron; Rupa Bandyopadhyay; Anna Genin; Michael Brunner; Gilbert J Kersh; Jiyi Yin; Terri H Finkel; Mary K Crow
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

2.  Endothelial cell and cAMP regulation of T-cell CD40 ligand: relevance of calcium/calmodulin-dependent kinase IV signalling.

Authors:  Christopher P Nielson; Denise Wingett
Journal:  Immunology       Date:  2002-04       Impact factor: 7.397

3.  Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines.

Authors:  S Gummuluru; M Emerman
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 4.  CD154 transcriptional regulation in primary human CD4 T cells.

Authors:  Randy Q Cron
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

5.  Human neonatal naive CD4+ T cells have enhanced activation-dependent signaling regulated by the microRNA miR-181a.

Authors:  Amy C Palin; Vasavi Ramachandran; Swati Acharya; David B Lewis
Journal:  J Immunol       Date:  2013-02-13       Impact factor: 5.422

6.  The impact of Nucleofection® on the activation state of primary human CD4 T cells.

Authors:  Mingce Zhang; Zhengyu Ma; Nithianandan Selliah; Greta Weiss; Anna Genin; Terri H Finkel; Randy Q Cron
Journal:  J Immunol Methods       Date:  2014-06-05       Impact factor: 2.303

7.  A T-cell-specific CD154 transcriptional enhancer located just upstream of the promoter.

Authors:  M Brunner; M Zhang; A Genin; I-C Ho; R Q Cron
Journal:  Genes Immun       Date:  2008-08-21       Impact factor: 2.676

8.  Delineation of a novel pathway that regulates CD154 (CD40 ligand) expression.

Authors:  B JoNell Hamilton; Anna Genin; Randy Q Cron; William F C Rigby
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

9.  Influence of nanoparticle-mediated transfection on proliferation of primary immune cells in vitro and in vivo.

Authors:  Susanne Przybylski; Michaela Gasch; Anne Marschner; Marcus Ebert; Alexander Ewe; Gisa Helmig; Nadja Hilger; Stephan Fricke; Susanne Rudzok; Achim Aigner; Jana Burkhardt
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

10.  Sendai F/HN viroplexes for efficient transfection of leukemic T cells.

Authors:  Jung Seok Kim; Yeon Kyung Lee; Hwa Yeon Jeong; Seong Jae Kang; Min Woo Kim; Seung Hyun Ryu; Hong Sung Kim; Keun Sik Kim; Dong-Eun Kim; Yong Serk Park
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.